ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1)

Class

Enzyme replacement therapy (recombinant ENPP1-Fc fusion protein, rhENPP1-Fc)

Pathway

ATP → extracellular inorganic pyrophosphate (PPi) generation — ectopic/vascular calcification pathway (ENPP1/ABCC6 deficiency; also studied in hemodialysis-associated vascular calcification)

Notes

original target text: ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) — enzyme replacement

ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) is a cell-surface and secreted enzyme that converts extracellular ATP into AMP and inorganic pyrophosphate (PPi). PPi is one of the body's principal natural inhibitors of hydroxyapatite crystal formation, the mineral that makes up bone but which, when deposited inappropriately in soft tissue, causes pathological calcification. When ENPP1 activity is insufficient, whether from inherited loss-of-function mutations or from disease states that suppress its activity, PPi levels fall and calcium-phosphate crystals can deposit in arteries, joints, and other tissues that are normally protected from mineralization. This underlies rare genetic disorders of early-onset arterial and periarticular calcification, and it is also studied in acquired settings such as vascular calcification associated with kidney failure, where mineral handling is broadly disrupted. Enzyme replacement therapy with a recombinant ENPP1 fused to an antibody fragment (Fc) is designed to restore circulating enzymatic activity and normalize PPi generation systemically, addressing the underlying enzymatic deficit rather than only managing its downstream consequences. The Fc fusion serves mainly to extend the protein's circulating half-life, allowing less frequent dosing than the native enzyme would permit. This mechanism is of interest broadly wherever pathological calcification arises from deficient pyrophosphate generation, spanning both genetic and acquired disease contexts.